Morgan Stanley maintains "overweight" rating on Eli Lilly

2025-06-23 17:59:14

Morgan Stanley maintained its "overweight" rating on Eli Lilly with a target price of $1,133.

Lilly

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.
                            2025-07-30

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.
                            2025-07-30

                                    BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.
                            2025-08-01